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Abstract
Background and aims Intra-operative parathyroid hormone
(IOPTH) results are not known in the setting of tertiary
hyperparathyroidism (HPT) after renal transplantation.
Materials and methods A retrospective analysis of 35
tertiary HPT patients who all underwent subtotal parathy-
roidectomy and IOPTH monitoring was conducted.
Results The mean follow-up time was 2.2±1.4 years.
Thirty-four patients were cured; one patient (2.8%) had a
persistent disease and was cured after reoperation. Median
parathyroid hormone (PTH) (median percent decrease from
highest) at baseline and at 5, 10, 20, and 30 min were 244,
78 (69%), 63 (75%), 53 (79%), and 49 pg/ml (83%),
respectively. Four patients who were cured had a decrease
of <50% at 5 min and two of them had a decrease of <50%
at 10 min. The patient with persistent disease had a
decrease of >50% at 10 min. The sensitivity of the test
was 94% at 10 min using the Miami criteria.
Conclusion This study shows that IOPTH in tertiary
hyperparathyroidism has a high sensitivity. However,
because of the low risk of persistent hyperparathyroidism
when a subtotal parathyroidectomy is performed, its
potential impact on the overall success rate is very small.
We therefore do not recommend the routine use of IOPTH
in tertiary hyperparathyroidism.
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Introduction
In patients with tertiary hyperparathyroidism (HPT), even
when renal function returns to normal after kidney
transplantation, the secretion of parathyroid hormone
(PTH) does not. The reason for this is because PTH
secretion has become autonomous and no longer responses
to calcium and calcitriol levels. The association of normal
renal function and high PTH level leads then to hypercal-
cemia. When hypercalcemia persists for more than 1 year
after kidney transplantation or when patients develop
complication related to hyperparathyroidism, parathyroid-
ectomy is currently the only available curative treatment.
The standard surgical approach for patients with tertiary
hyperparathyroidism is subtotal parathyroidectomy or total
parathyroidectomy with autotransplantation [1–7]; howev-
er, some authors have advocated a less-than-subtotal
resection in some patients, describing up to one third of
their patients with limited gland involvement (single or
double ‘adenoma’) [8–11]. Because it is sometimes difficult
to find all parathyroid glands, particularly when patients
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have more than four glands, and to leave a remnant of
adequate size (big enough to avoid hypoparathyroidism but
small enough to avoid persistent and recurrent disease), it
would be helpful to have a reliable intra-operative indicator
of cure. Intra-operative parathyroid hormone (IOPTH) has
been proven to be helpful in primary HPT, particularly
when a unilateral approach is used, and it has an accuracy
of >95% in this setting [12–17]. If IOPTH has the same
sensitivity and specificity in tertiary HPT, it could help
define the extent of parathyroidectomy. The accuracy of
IOPTH in renal HPT is not clearly described and different
authors have described conflicting results [18–20]. More-
over, many papers describe IOPTH independently of the
renal function (in patients under dialysis and patients after
kidney transplantation) [18, 20] and few have focused their
attention on patients with tertiary HPT after kidney
transplantation.
Moreover, because tertiary hyperparathyroidism is a
unique situation in which a multiglandular disease is
associated with normal renal function in most of the
patients, the results of IOPTH in this situation could help
understand how to interpret the IOPTH results in patients
with primary hyperparathyroidism and multiglangular dis-
ease. The aim of this study was to assess the accuracy of
IOPTH in tertiary hyperparathyroidism and to describe the
results according to the renal function.
Materials and methods
Between January 1998 and December 2003, 35 consecutive
patients were operated in our center for tertiary hyperpara-
thyroidism, as defined by persistently high calcium and
PTH levels after kidney transplantation. The criteria for
surgery were asymptomatic persisting hypercalcemia
(>10.5 mg/dl) with an inappropriately high PTH level or
the presence of signs or symptoms of tertiary HPT with
elevated PTH, usually more than 1 year after kidney
transplantation.
All patients underwent a complete bilateral neck para-
thyroid exploration, a transcervical thymectomy, and a
subtotal parathyroidectomy, leaving a single remnant of the
size of two normal parathyroid glands, as previously
described [7]. All patients underwent IOPTH monitoring.
Peripheral blood samples were withdrawn at anesthesia
induction, before excision of the first parathyroid gland and
5, 10, 20, and 30 min after excision of the last parathyroid
gland. Intra-operative intact PTH levels were measured
using a commercially available two-site assay (Nichols
Institute Diagnostics, San Juan Capistrano, CA, USA;
normal range 10–60 pg/ml). This assay is known to detect
1–84 PTH and other fragments, including 7–84 PTH [21].
The percentage of decrease was calculated using the highest
of the two pre-excision values, and the Miami criteria were
used to define a positive or negative IOPTH result
(decrease of >50% from highest value 10 min after
resection of the last gland).
The post-operative PTH level was always intact PTH,
measured by a standard radioimmunometric assay (refer-
ence range 10–60 pg/ml). The serum calcium levels were
corrected to the protein level using standard formulas.
Hypoparathyroidism was defined as hypocalcemia and/or
infranormal PTH level (<10 pg/ml). Persistent or recurrent
disease was defined as hypercalcemia (serum calcium level
>10.5 mg/dl) and/or PTH level above the recommended K/
DOQI target range according to renal function [22] during
the first 6 months after parathyroidectomy and after
6 months, respectively. Glomerular filtration rate (GFR)
was calculated using the Cockroft and Gault formula.
The results are presented as mean values±standard
deviation unless otherwise stated. Statistical analysis was
performed with SPSS 11.0.1 (SPSS, Chicago, IL, USA).
Graphs were created with SPSS and legends were added
with Adobe Photoshop Elements (Adobe Systems, San
Jose, CA, USA) when needed. Comparisons between pre-
and post-operative serum calcium and PTH level were
made with paired-samples t test. A p value was considered
statistically significant when <0.05.
Results
Surgical results
There were 35 patients, 18 men and 17 women. The
duration of dialysis before kidney transplantation was
2.7±2.8 years. The time between kidney transplantation
and parathyroidectomy was 5.3±5.1 years. The age at
parathyroidectomy was 47±11 years. GFR at parathyroid-
ectomy was 53±21 ml/min. The preoperative calcium level
was 11.2±1.0 mg/dl and PTH level was 306±340 pg/ml.
All patients underwent a bilateral neck exploration with
subtotal parathyroidectomy and transcervical bilateral thy-
mectomy. During the operation, four cervical glands were
found in all patients. Hyperplastic glands were found in all
patients at microscopic examination. Parathyroid hyperpla-
sia was defined as an increased parenchymal mass in the
absence of a rim of compressed parathyroid tissue [23]. The
total excised parathyroid tissue weighed 1,073±775 mg.
There was no post-operative death. Two patients under
anticoagulant therapy were reoperated for hemorrhage and
eight patients had transient ‘simple’ hypocalcemia (with-
out hypocalcemia-related complications). At day 1, the
calcium level was 8.3±1.0 mg/dl and the PTH level was
28±14 pg/ml. Follow-up was available for all patients and
was 2.2±1.4 years. One patient died of cardiovascular
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complication; one patient was on dialysis again. At
follow-up, GFR was 49±25 ml/, serum calcium level
was 9.1±0.7 mg/dl, and PTH level was 66±48 pg/ml. One
patient presented with a persistent disease and underwent
a successful re-excision of the parathyroid remnant. At
follow-up, no patient was hypoparathyroid and all had
PTH level in the target range recommended by the
K/DOQI [22].
IOPTH results
As shown in Fig. 1, less than 50% of the patients reached
normal PTH level 10 min after the resection of the last
gland (median value at 10 min, 63 pg/ml). At 30 min, 12
patients (34%) still had PTH values above the normal
range. When the percentage of decrease is studied, IOPTH
did not decrease by >50% in two patients who were cured
at 10 min, while all patients had a decrease of >50% at
20 min, including the patient with a persistent disease
(Fig. 2). The sensitivity of IOPTH was 94% and the
positive predictive value was 97% using the Miami criteria.
However, the specificity and the negative predictive value
could not be calculated because only one patient had a
persistent disease and no patient had a true negative IOPTH
result (less than 50% decrease with persistent disease).
Taking the renal function into account did not add any
precision at 10 min; in effect, more than 50% of the patients
in both groups had a PTH value above the normal range
(the median PTH value was 70 pg/ml in the group with a
GFR <60 ml/min and was 61 pg/ml in the group with a
GFR >60 ml/min). However, at 30 min, only 2 (13%) of the
15 patients in the ≥60 ml/min group did not have PTH level
in the normal range, while 11 (55%) of the 20 patients in
the group <60 ml/min were in that situation. (Fig. 3). One
patient who was cured in each group had a <50% decrease
at 10 min.
Discussion
This study shows that IOPTH during parathyroidectomy for
tertiary hyperparathyroidism after renal transplantation has
Fig. 1 Boxplots representing the PTH level according to the timing of
blood sampling. The dotted line represents the normal limit for our
assay. Outliers outside the graph range are shown with their individual
values
Fig. 2 Boxplots showing the percent of PTH calculated as percentage
from the highest of the two pre-excision values (at anesthesia
induction and before the last parathyroid gland resection)
Fig. 3 Boxplots representing the PTH level at different time intervals
according to the GFR. The dotted line represents the normal limit for
our assay. Outliers outside the graph range are shown with their
individual values
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a high sensitivity (94%) and positive predictive value (97%)
using the Miami criteria for cure (decrease of >50% from
highest value 10 min after excision of the last parathyroid
gland). However, because only one patient had a persistent
or recurrent hyperparathyroidism and no patient had a true
negative test, the specificity and negative predictive value
could not be calculated.
Thanks to the short half-life of PTH (1 to 3 min) in
patients with normal renal function, IOPTH has been
developed as a reliable tool to predict the success of
parathyroidectomy in primary hyperparathyroidism [12, 13,
24]. However, PTH half-life is increased in patients with
renal insufficiency, due not only to a prolonged half-life of
the 1–84 PTH but also to the particularly prolonged half-
life of the 7–84 fragment, co-detected by most of the
standard PTH assays [18, 19, 21, 25, 26]. Therefore, the
accuracy of IOPTH in patients with renal insufficiency is
debated on and its ability to predict cure or failure is highly
variable according to the parameters studied [18–20, 25,
27]. After renal transplantation, most of the patients retrieve
good renal function; however, the accuracy of IOPTH in
patients with tertiary hyperparathyroidism is not known.
Previous reports have shown that IOPTH changed the
management in 5 of 32 patients studied with only one false
positive result; however, the long-term cure rate is given by
the calcium level only and not the PTH level in this study
[28]. Because of the retrospective nature of our study, the
IOPTH did not change the management of any of the 35
patients. However, even if performed in a prospective way,
it could have led to an unnecessary, more aggressive
resection in two patients who had a false-negative IOPTH
result and it would not have permitted to cure the patient
who had persistent disease as he had a false-positive result.
Taking renal function into account increases the accuracy of
the IOPTH; however, it was only at 30 min after the
resection of the last gland in this study, rendering this test
less useful because of the waiting time associated to such a
long delay.
In this study, 20 of the 35 patients (57%) had
GFR <60 ml/min, showing a significant decrease in renal
function despite the renal graft, which is in accordance with
the relatively long time interval between renal transplanta-
tion and parathyroidectomy (5.3 years in this study) and
with the natural history of renal transplantation [29]. At this
stage of renal insufficiency, bone resistance to PTH
increases, PTH secretion is stimulated, and PTH and its
fragments begin to accumulate [22]. The increase in PTH
levels makes it difficult to reach the true normal range
during parathyroidectomy because of the sometimes very
high preoperative PTH levels (maximum of 3,190 pg/ml in
this study). Moreover, the increased PTH half-life (whole
and fragments) seen in renal insufficiency [18, 19, 30]
makes it difficult to achieve a significant and reproducible
decrease in a reasonable amount of time. Different criteria
for cure have been proposed for IOPTH in renal hyperpara-
thyroidism such as >50% decrease at 20 min [18], >82% at
15 min [20], or >60% at 10 min [19]. However, none of
them could predict cure or failure in 100% of the patients.
Our study in patients with tertiary hyperparathyroidism
confirms this and no criteria had an accuracy of 100%.
Two recent reports show an increased accuracy when the
newest whole-PTH assay was used. Yamashita et al. [31]
had a decline of >50% in 17 of 18 patients with renal
hyperparathyroidism and Kaczirek et al. [30] showed that
IOPTH fell in the normal range only after adequate
resection in 30 of 30 patients (total or subtotal parathyroid-
ectomy) and could predict insufficient resection in four of
the five patients who had persistent hyperparathyroidism. In
our study, we have used a first-generation IOPTH assay and
further investigations are needed to confirm the increased
accuracy of whole-PTH assay in the management of tertiary
hyperparathyroidism after renal transplantation.
In conclusion, this study shows that IOPTH has a high
sensitivity and positive predictive value in tertiary hyper-
parathyroidism, meaning that it is able to correctly predict
cure when the patient is cured. However, such a test is most
useful when the patient is not cured and, with a systematic
subtotal parathyroidectomy and cervical thymectomy,
the risk appears to be small and the potential benefit of
IOPTH seems to be very low, particularly with the assays
co-detecting PTH fragments. We therefore do not recom-
mend the routine use of IOPTH in tertiary hyperparathy-
roidism when a systematic subtotal parathyroidectomy is
performed.
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